Adults and children with all genotypes of hepatitis C and compensated cirrhosis: Mavyret shortens duration of treatment to eight weeks, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has expanded the approval of Mavyret ( Glecaprevir and Pibrentasvir ) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus ( HCV ) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV ( treatment-naïve ).
Mavyret is now the first eight-week treatment approved for all treatment-naïve adult and certain pediatric patients with HCV genotypes 1-6 both without cirrhosis and with compensated cirrhosis.
Standard treatment length for patients with compensated cirrhosis was previously 12 weeks or more.
HCV is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.
According to the U.S. Centers for Disease Control and Prevention ( CDC ), an estimated 2.7 to 3.9 million people in the U.S. have chronic HCV, and children born to HCV-positive mothers are at risk for HCV infection.
Researchers estimate there are 23,000 to 46,000 children in the U.S. with HCV infection.
The efficacy and safety of Mavyret was established in clinical trials, which cumulatively evaluated more than 2,500 people with HCV genotype 1, 2, 3, 4, 5 or 6 infection who received Mavyret for eight, 12 or 16 weeks duration.
The trials included patients with HIV-co-infection, kidney or liver transplant recipients and patients with advanced kidney disease, including those requiring hemodialysis.
The efficacy of HCV treatment regimens are measured by the proportion of people in clinical trials achieving virologic cure.
Virologic cure is the lack of detectable HCV in the blood at certain time points after completion of HCV therapy, known as sustained virologic response ( SVR ).
SVR at 12 weeks post-treatment ( SVR 12 ) is the standard measure of virologic cure.
SVR 12 rates for Mavyret have ranged from 91-100% across clinical trials.
The most common adverse reactions in patients taking Mavyret are headache and fatigue.
Mavyret is contraindicated in patients with moderate or severe liver impairment ( Child-Pugh B or C ) or in those with any history of liver decompensation. It is also contraindicated in patients taking the drugs Atazanavir and Rifampin. ( Xagena )
Source: FDA, 2019
The nucleoside-modified messenger RNA in COVID-19 mRNA vaccine BNT162b2 is formulated in lipid nanoparticles, which enable delivery of the RNA...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...
Initial preliminary findings from the Papa Giovanni XXIII Hospital sponsored SISCO ( Siltuximab In Serious COVID-19 ) Study, based on...
Results from the largest study of hepatitis B and C and HIV infection prevalence in cancer patients show an alarmingly...
FDA has approved Dovato, the first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment
The FDA ( U.S. Food and Drug Administration ) has approved Dovato ( Dolutegravir and Lamivudine ), as a complete...
Dovato, based on Dolutegravir and Lamivudine, a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection, approved in European Union
The European Commission has granted Marketing Authorisation for Dovato ( Dolutegravir / Lamivudine ) for the treatment of HIV-1 infection...
The results of a study has shown that patients living with HIV and one of a variety of potentially deadly...
HIV-1 control with a 2-drug regimen of Dolutegravir plus Lamivudine in virally suppressed patients switching from a TAF-containing 3-drug regimen
Week 48 results from phase III TANGO study were announced. The TANGO study was conducted to assess whether adults living...
Biktarvy: Bictegravir, Emtricitabine, Tenofovir Alafenamide approved by FDA for treatment of HIV-1 infection
The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...